-transparent.png){kind=logo}
Asthma is a respiratory disease that affects people of all walks of life, and is a hotspot of continuous research, with significant manpower and resources invested in its study. Airway remodeling is an important associated pathological change, and a mark of the irreversible damage produced by asthma. It involves compositional and functional changes in the cells of the airway walls, leading to reversible structural changes, and complicating treatment. Airway remodeling is mediated by different inflammatory pathways which have been targeted for treatment, with good results. However, given its complexity, systematic study of the pathogenesis of airway remodeling is still needed, and additional targeted therapies are necessary. Macrolide drugs, such as erythromycin, azithromycin, and clarithromycin, have antibacterial effects and also influence the cytokine secretion of macrophages and T-lymphocytes. They have direct effects on a variety of cytokines, inhibiting inflammation and reducing airway reactivity. In this study, we investigated the protective effect of azithromycin on airway remodeling through the phosphoinositol-3 kinase/Akt/mechanistic target of rapamycin kinase/hypoxia-inducible factor 1α (HIF-1α)/vascular endothelial growth factor (VEGF) pathway. We observed that a long course of azithromycin could significantly reduce airway reactivity and ovalbulmin-induced pathological alterations in asthmatic mice. Gene expression analysis confirmed that HIF-1α and VEGF were significantly down-regulated following a long course of azithromycin administration.
X Zhao, and
F Q Yu, and
X J Huang, and
B Y Xu, and
Y L Li, and
X Y Zhao, and
H F Guo, and
B Luan
January 2021,
Ear, nose, & throat journal,
X Zhao, and
F Q Yu, and
X J Huang, and
B Y Xu, and
Y L Li, and
X Y Zhao, and
H F Guo, and
B Luan
March 2018,
Journal of experimental & clinical cancer research : CR,
X Zhao, and
F Q Yu, and
X J Huang, and
B Y Xu, and
Y L Li, and
X Y Zhao, and
H F Guo, and
B Luan
January 2021,
Frontiers in pharmacology,
X Zhao, and
F Q Yu, and
X J Huang, and
B Y Xu, and
Y L Li, and
X Y Zhao, and
H F Guo, and
B Luan
August 2023,
Journal of nanobiotechnology,
X Zhao, and
F Q Yu, and
X J Huang, and
B Y Xu, and
Y L Li, and
X Y Zhao, and
H F Guo, and
B Luan
September 2018,
Biochemical and biophysical research communications,
X Zhao, and
F Q Yu, and
X J Huang, and
B Y Xu, and
Y L Li, and
X Y Zhao, and
H F Guo, and
B Luan
April 2016,
Oncotarget,
X Zhao, and
F Q Yu, and
X J Huang, and
B Y Xu, and
Y L Li, and
X Y Zhao, and
H F Guo, and
B Luan
August 2012,
Phytotherapy research : PTR,
X Zhao, and
F Q Yu, and
X J Huang, and
B Y Xu, and
Y L Li, and
X Y Zhao, and
H F Guo, and
B Luan
January 2022,
Biochemical and biophysical research communications,
X Zhao, and
F Q Yu, and
X J Huang, and
B Y Xu, and
Y L Li, and
X Y Zhao, and
H F Guo, and
B Luan
May 2014,
Experimental and therapeutic medicine,
X Zhao, and
F Q Yu, and
X J Huang, and
B Y Xu, and
Y L Li, and
X Y Zhao, and
H F Guo, and
B Luan
January 2020,
Experimental lung research,
